Determinants of eHealth Literacy among Adults in China.

eHealth can empower patients to make informed health decisions. However, inaccurate and misleading health information is not uncommon on the Internet, which requires users' competencies to both utilize eHealth technologies and evaluate eHealth credibilities. Therefore, this study investigates the determinants of both self-efficacy in utilizing eHealth and frequency of eHealth information evaluation. An Internet-based survey of 923 Chinese adults who are residing in China aged from 21 to 55 years old was conducted. Path analysis was adopted to examine sociodemographic variables, Internet literacy, and health information evaluation as determinants of eHealth literacy variables. Findings demonstrated that Internet literacy positively predicted only self-efficacy in utilizing eHealth. In contrast, health information orientation positively predicted both self-efficacy in utilizing eHealth and frequency of eHealth information evaluation. In addition, Internet literacy and health information orientation mediated the predicted effects of sociodemographic factors on the two eHealth variables. The findings imply that Internet literacy is no longer the primary determinant of eHealth competencies for adults who are tech-savvy users. Instead, interests in health information play a crucial role in improving eHealth competencies.

Characterization of human E4BP4, a phosphorylated bZIP factor.

In this report we described the isolation of transcription factor E4BP4 by lambda gt11 expression cloning using a probe containing the CRE/ATF-like sequence located between -2764 bp and -2753 bp in the upstream regulatory region for the human IL-1 beta gene. DNaseI protection, gel mobility shift analysis, and cotransfection studies were performed to investigate the binding and functional properties of E4BP4 using IL-1 beta promoter sequences. By DNaseI footprinting, a protection pattern was generated over the CRE/ATF-like site and the flanking sequences by bacterially produced E4BP4. Competition experiment by gel shift assay indicated that E4BP4 bound specifically to CRE/ATF-like site, not NF kappa B-like site. In cotransfection studies, E4BP4 repressed promoter activity and this repression was mediated through the CRE/ATF-like site. Mutational analysis of E4BP4 suggested that the DNA binding as well as repression activities required leucine heptad repeat domain. Analysis of E4BP4 produced in Escherichia coli and Sf9 cells infected with recombinant baculovirus indicated that baculovirus produced protein showed enhanced binding to the CRE/ATF-like site compared to the E. coli-produced protein. Analysis of posttranslational modifications indicated that E4BP4 produced in Sf9 cells was phosphorylated and this phosphorylation was important for the DNA binding activity of E4BP4.

Randomized trial comparing continuous subcutaneous insulin infusion and conventional insulin therapy in type II diabetic patients poorly controlled with sulfonylureas.

OBJECTIVE: To compare the effects of continuous subcutaneous insulin infusion (CSII) and conventional insulin therapy (CIT) in patients with poorly controlled sulfonylurea-treated diabetes mellitus. RESEARCH DESIGN AND METHODS: Twenty-five patients aged 40-65 yr and poorly controlled with sulfonylureas and without severe diabetic complications comprised the study group. Five patients left the study (3 achieved satisfactory glycemic control without insulin, 1 defaulted, 1 developed ketonuria). Ten patients were treated with CSII and 10 with CIT. Outpatient treatment consisted of CIT (twice-daily injections of regular and NPH insulin) or CSII (basal infusion and prandial boluses of regular insulin). RESULTS: Glycosylated hemoglobin improved with both methods of insulin delivery (P less than 0.01), but 8 of 10 CSII-treated patients achieved satisfactory glycemic control (HbA1 less than 50 mmol hydroxymethylfurfural/mol Hb), whereas only 3 of 10 CIT-treated patients achieved this (P less than 0.05). Weight gain, insulin dosage, and prevalence of hypoglycemia were similar in the two groups. Retinal deterioration occurred in one CSII-treated patient and three CIT-treated patients, but there were no episodes of infusion site infection or metabolic decompensation. Patients' satisfaction with treatment improved during insulin therapy (P less than 0.02), and significant changes in beliefs about diabetes and its treatment were observed in CSII-treated patients (P less than 0.05). CONCLUSIONS: Glycemic control improved with both methods of insulin treated patients achieved satisfactory glycemic control (HbA1 less than 50 mmol hydroxymethylfurfural/mol Hb), whereas only 3 of 10 CIT-treated patients achieved this CSII. Patients' satisfaction with treatment improved during insulin therapy.

Analysis of pain management in critically ill patients.

We analyzed the adequacy of pain control for 17 trauma patients during the initial part of their stay in the intensive care unit, and assessed reasons for inadequate analgesia, if it occurred. Patients, and physicians, and nurses were interviewed. A verbal pain intensity scale was used to determine whether patients received adequate analgesia. Patients were asked if the pain hindered their activities, and whether they requested pain medication from their caregivers. Caregivers were questioned whether patients received adequate analgesia. Prescribed morphine regimens and the amount of narcotic administered were analyzed. Twenty-seven percent of patients rated pain intensity as moderate and 47% as severe. Ninety-five percent of housestaff and 81% of nurses reported the patients received adequate pain control. Forty-seven percent of the patients who had moderate or severe pain asked their physician for more pain medication, and 65% asked the nurse. Thirteen residents did not order a larger dose of morphine due to concern about respiratory depression or hypotension. Morphine dosages ranged from 1-8 mg intravenously every 1-2 hours as necessary. Nurses administered less than the maximum amount ordered 58% of the time. The mean dosing interval was 2.3 hours. Barriers to adequate pain management were disparity in the perception of pain between patients and caregivers; patients not requesting more analgesia despite despite the presence of moderate to severe pain; and physician and nurse concerns about patients' adverse physiologic response to increased dosages.

Pharmacokinetic evaluation of a new oral cyclosporine formulation.

STUDY OBJECTIVE: To compare the pharmacokinetics of a new oral cyclosporine preparation with those of cyclosporine solution diluted in Isocal and the intravenous formulation. DESIGN: Randomized, crossover trial. SETTING: Tertiary care referral center. PATIENTS: Seven pediatric liver transplant recipients who were receiving oral cyclosporine as part of their immunosuppressive regimen. All patients completed the study. INTERVENTIONS: Pharmacokinetic studies were performed with the intravenous and oral dosage forms. Patients received one dose of intravenous cyclosporine, and then were randomized to receive their usual oral cyclosporine dose incorporated into a chocolate wafer or mixed with Isocal. After a minimum of 3 days, the alternative preparation was administered. Serial cyclosporine blood samples were collected at predetermined intervals for 12 hours after the third dose for each regimen. Concentrations were determined by high-performance liquid chromatography. The data for the three dosage forms were fit simultaneously with a two-compartment model. MEASUREMENTS AND MAIN RESULTS: No difference was seen in F, ka, Cmax, and tmax between the two oral cyclosporine preparations (p > 0.05). No new rejection episodes occurred during the study period. CONCLUSIONS: We conclude there is no difference in the bioavailability of the oral solution and the chocolate formulation. We believe the new preparation may increase patient compliance and ensure administration of a complete dose compared with the currently marketed solution.

Current patterns of prescribing and administering morphine in trauma patients.

We attempted to characterize the current prescribing practices and administration patterns for intravenous intermittent morphine in trauma patients in a multicenter, open prospective, observational study. The subjects were 141 patients admitted to the surgical intensive care units (ICU) of five United States trauma centers within 12 hours of injury who received intermittent intravenous morphine for pain relief. The study was conducted from April 15, 1992, to February 15, 1993. Data obtained during the first 32 hours of the ICU stay included morphine regimen, doses administered, and time between doses. One hundred sixty-one orders were prescribed by surgeons. The most frequently ordered dose was 2-4 mg and the most frequently ordered interval was every hour as necessary. There was no relationship between the severity of injury and the minimum dose ordered. During the 492 nursing shifts studied, 1257 doses were administered. Of these, 44% were at or below the minimum amount prescribed by the surgeons. Thirty-three percent of the patients received a dose at an interval of more than 3 hours. We concluded that small amounts of narcotic analgesics are given to severely injured patients, and amount ordered is not affected by the severity of injury.

Chemical conditions inside occluded regions on corroding aircraft aluminum alloys.

Corrosion of aluminum alloy structures costs the US Air Force in the order of US$1 x 10(9) annually. Corrosion develops in areas of overlap such as aircraft lap-splice joints and under protective organic coatings. Capillary electrophoresis (CE) has been used to determine the local chemistries at these corrosion sites of solutions that were extracted using a microsampling system. Analysis of the local solution within lap-splice joints from aircraft has been performed in two ways: rehydration of corrosion products and direct microsampling. The solutions collected were analyzed with CE to quantitatively determine the species present during corrosion. The most common ions detected were Cl-, NO2-, NO3-, HCO3-, K+, Al3+, Ca2+, Na+ and Mg2+. Studies of the solution chemistry under local coating defects are required to understand coating failure and develop more durable coatings. A microsampling system and micro pH sensor were developed to extract solution from and measure pH in defects with diameters as small as 170 microns. Actively corroding defects contained high concentrations of Cl-, Al3+, Mg2+, Mn2+ and Cu2+ whereas only trace levels of Mg2+ were found in repassivated defects. The effects of these species on initiation and propagation of corrosion are discussed.

Tramadol: a new centrally acting analgesic.

The pharmacology, pharmacokinetics, efficacy, adverse effects, and dosage and administration of tramadol are reviewed. Tramadol is a synthetic analogue of codeine that binds to mu opiate receptors and inhibits norepinephrine and serotonin reuptake. It is rapidly and extensively absorbed after oral doses and is metabolized in the liver. Analgesia begins within one hour and starts to peak in two hours. In patients with moderate postoperative pain, i.v. or i.m. tramadol is roughly equal in efficacy to meperidine or morphine; for severe acute pain, tramadol is less effective than morphine. Oral tramadol can also be effective after certain types of surgery. Tramadol and meperidine are equally effective in postoperative patient-controlled analgesia. In epidural administration for pain after abdominal surgery, tramadol is more effective than bupivacaine but less effective than morphine. In patients with ureteral calculi, both dipyrone and butylscopolamine are more effective than tramadol. For labor pain, i.m. tramadol works as well as meperidine and is less likely to cause neonatal respiratory depression. Oral tramadol is as effective as codeine for acute dental pain. In several types of severe or refractory cancer pain, tramadol is effective, but less so than morphine; for other types of chronic pain, such as low-back pain, oral tramadol works as well as acetaminophen-codeine. Common adverse effects of tramadol include dizziness, nausea, dry mouth, and sedation. The abuse potential seems low. The recommended oral dosage is 50-100 mg every four to six hours. Tramadol is an effective, if expensive, alternative to other analgesics in some clinical situations.

Systemic lupus erythematosus: the great masquerader.

Systemic lupus erythematosus is a chronic systemic autoimmune collagen vascular disease that can present itself in many forms throughout any system in the body. Classification, etiology, diagnosis, course of the illness with flares and remission, prognosis, treatment and emotional coping are covered. Five tables outline lab tests, classification of symptoms by tissues primarily affected, drugs used, dietary suggestions and symptoms which need the attention of a health care provider.

Medical record review for clinical pertinence.

This clinical pertinence review process described was in effect for seven months, after which the author terminated affiliation with the hospital. Despite resistance by many physicians, this monthly review process focused the medical staff's attention on good documentation practices. To the author's knowledge, the plan is still in use.

Emotional adjustment to a chronic illness.

The emotional reaction to the diagnosis of a chronic illness can be a greater challenge than coping with the physical manifestations of the illness. This article describes and explains the determinants of the emotional reaction to the diagnosis of a chronic illness: (1) personality before the illness; (2) unresolved anger or grief from the past; (3) the suddenness, extent, and duration of life-style changes mandated by the illness; (4) familial and individual resources for dealing with stress; (5) stages of individual and family life cycle; (6) previous experience with illness or crisis; and (7) codependency in the family system. Also discussed are the stages of integrating grief process with the benefits and pitfalls of each stage and signs of acceptance. The benefits and necessity of going through the grief process are explored. People who receive diagnoses of chronic illness may find their emotional reaction more disabling than the illness itself until they go through the adjustment process to embrace the new person they have become through the illness.

Measures of psychological well-being and treatment satisfaction developed from the responses of people with tablet-treated diabetes.

Psychological outcome measures of Well-being and Treatment Satisfaction have been designed and developed for people with tablet-treated Type 2 diabetes. The Well-being scale includes three six-item sub-scales to measure Depression, Anxiety, and Positive Well-being. A prime consideration when selecting items for the psychological well-being measures was to minimize the confounding of diabetic symptomatology with the somatic symptoms of depression and anxiety. Cronbach's alpha indicated that each of the Well-being sub-scales and the Treatment Satisfaction scale was internally reliable (alphas ranged from 0.70 to 0.88) and evidence for construct validity was provided by predicted associations with other variables collected at the time of the study. For example, lower Well-being scores were associated with being overweight (Depression: p less than 0.05; Anxiety: p less than 0.001) while greater Satisfaction with Treatment was associated with lower HbA1 levels (p less than 0.001) and lower percent ideal body weight (p less than 0.01). These scales should prove particularly useful where measures of quality of life are required to complement metabolic variables when evaluating new treatments, education programmes, and other interventions, or in the routine auditing of established methods of treatment.

Intrathecal baclofen for severe spasticity secondary to spinal cord injury.

OBJECTIVE: To evaluate the use of intrathecal baclofen for the treatment of muscle spasticity in patients with spinal cord injury. DATA SOURCES: A MEDLINE search was used to identify relevant and pertinent literature. Information was obtained from open-label clinical trials, abstracts, conference proceedings, and review articles. Index terms in the search included baclofen, spasticity, intrathecal drug infusion, spinal cord disease, and neurosurgery. DATA EXTRACTION: Studies were selected for review if they evaluated intrathecal baclofen in patients with spinal cord injury. Emphasis was placed on human studies published in the English language. Trials were reviewed by dosage regimen, therapeutic response, adverse effects, and complications. DATA SYNTHESIS: Thus far, intrathecal baclofen administration shows promise in the treatment of spasticity resulting from spinal cord trauma. Few complications and adverse effects have been reported. CONCLUSIONS: Muscle spasms and spasticity constitute a significant problem in spinal cord injuries, interfering with rehabilitation and leading to inconveniences and complications in these patients. Oral baclofen is the drug of choice for spasticity due to spinal cord trauma. It often is ineffective, however, because of the large dosages required to cross the blood-brain barrier and the subsequent appearance of central nervous system adverse effects. These adverse effects are not tolerated by many patients. Intrathecally administered baclofen has been approved by the Food and Drug Administration (FDA) for the treatment of spasticity in patients with spinal cord injury who are refractory to or cannot tolerate oral baclofen. It is intended for use only in implantable pumps approved by the FDA for the administration of baclofen into the intrathecal space. Intrathecal administration achieves high concentrations in the spinal cord with small dosages, thus reducing the incidence of central nervous system adverse effects. To date, approximately 350 patients with spinal cord injury have been treated with intrathecal baclofen. Reductions in spasticity have been demonstrated in both open-label and placebo-controlled trials. Patients also often make substantial gains in activities of daily living. Few adverse effects and complications have been reported. However, tolerance to the clinical effects of intrathecal baclofen has been reported. Further studies are needed to determine specific patient populations that may benefit most from intrathecal baclofen administration. Individual dosage ranges and follow-up care also need to be defined more completely. In addition, the question of whether tolerance detracts from long-term clinical benefits with intrathecal baclofen needs to be addressed.

A measure of treatment satisfaction designed specifically for people with insulin-dependent diabetes.

The psychometric properties of a diabetes-specific treatment satisfaction scale were examined with responses from 128 adults with insulin-dependent diabetes who had used one of three treatment options for a period of 12 months. The reliability of the seven-item measured was found to be satisfactory (Cronbach's Alpha = 0.76) and factor analyses indicated three useful sub-scales (Perceived General Management; Perceived Compatibility with Lifestyle; Perceived Frequency of Hypo/hyperglycaemia). Use of the treatment satisfaction measure in a feasibility study of continuous subcutaneous insulin infusion (CSII) demonstrated the measure's ability to distinguish between three treatment groups (CSII, intensified conventional therapy and conventional therapy). People choosing to use CSII reported significantly greater improvements in satisfaction than those choosing either from of conventional therapy (F = 36.6; df 2, 125; p less than 0.001). If used in conjunction with measures of blood glucose control, the Treatment Satisfaction measure offers the opportunity for a more holistic appraisal of outcomes in studies evaluating and comparing treatments for insulin-dependent diabetes.

Scales to measure perceived control developed specifically for people with tablet-treated diabetes.

Scales to measure perceived control of tablet-treated diabetes were adapted from a measure designed previously for insulin users. Development of the new scale is described and the psychometric properties are examined with responses from 187 tablet-treated patients. The scales consist of seven subscales which may be combined to provide three composite scores indicating the extent to which respondents perceive Personal Control, Medical Control, and Situational Control over their diabetes. Relationships between subscales and composite scores were similar to those found previously for insulin users. Patients were significantly more likely (p less than 0.001) to make attributions to Personal Control for their diabetes management rather than to Medical or Situational Control. As before, predictable biases were found in attributions to positive and negative outcomes. Correlations with medical and other psychological variables indicated that, as expected, stronger perceptions of Personal Control were associated with lower HbA1 levels (r = -0.14; p less than 0.05), lower percent ideal body weight (r = -0.24; p less than 0.01), less Anxiety (r = -0.15; p less than 0.05), greater Positive Well-being (r = 0.21; p less than 0.01) and greater Satisfaction with treatment (r = 0.34; p less than 0.001). Complementary relationships were found with the measure of Situational Control. Wallston and Wallston's speculative Locus of Control typology was investigated using the new measures, and the findings provided support for the value of this approach.